JHS Svendgaard Laboratories Limited AI Stock Analysis
Want to see IN:JHS full AI Analyst Report?
JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis
JHS Svendgaard Laboratories Limited
(NSE:JHS)
The overall score is heavily weighed down by severe fundamental weaknesses, specifically persistent net losses, cash burn, and a highly unattractive valuation (negative P/E). While the stock currently enjoys strong technical momentum and benefits from a highly conservative balance sheet with minimal debt, poor operational execution severely limits its long-term viability and mutes the final score.
JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 704.49M
- Dividend Yield
- ―
- Average Volume (3M)
- 35.73K
- Price to Earnings (P/E)
- -56.3
- Beta (1Y)
- 0.43
- Revenue Growth
- 15.61%
- EPS Growth
- 85.89%
- Country
- India
- Employees
- 235
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
JHS Svendgaard Laboratories Limited Business Overview & Revenue Model
Company Description
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive product...
JHS Svendgaard Laboratories Limited Financial Statement Overview
Summary
A pristine balance sheet with exceptionally low leverage (0.085 D/E) provides a strong structural cushion, but overall financial execution remains poor. Five consecutive years of net losses, volatile profit margins, and deeply negative free cash flows significantly drag down the financial profile despite a recent rebound in top-line revenue.
Income Statement
35NegativeBalance Sheet
80PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.08B | 1.02B | 919.97M | 698.06M | 840.82M | 854.91M |
| Gross Profit | 222.32M | 177.22M | 309.55M | 203.55M | 165.45M | 201.68M |
| EBITDA | 32.15M | 60.64M | -39.92M | 33.78M | -163.82M | 85.45M |
| Net Income | -11.83M | -19.22M | -197.44M | -40.58M | -175.17M | -40.52M |
Balance Sheet | ||||||
| Total Assets | 2.16B | 2.15B | 2.01B | 1.97B | 2.28B | 2.22B |
| Cash, Cash Equivalents and Short-Term Investments | 49.26M | 191.00M | 200.16M | 94.56M | 386.51M | 80.19M |
| Total Debt | 142.44M | 148.51M | 64.58M | 51.29M | 155.09M | 61.82M |
| Total Liabilities | 395.40M | 405.49M | 284.41M | 271.70M | 543.87M | 269.46M |
| Stockholders Equity | 1.76B | 1.75B | 1.73B | 1.70B | 1.74B | 1.86B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -148.91M | -157.11M | -401.17M | 89.43M | -158.75M |
| Operating Cash Flow | 0 | -20.97M | -51.78M | -85.84M | 232.86M | -91.36M |
| Investing Cash Flow | 0 | -130.38M | -220.18M | -217.34M | 96.77M | -46.97M |
| Financing Cash Flow | 0 | 121.43M | 232.97M | 21.74M | -9.00M | -16.72M |
JHS Svendgaard Laboratories Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 8.10 is below the 20-day moving average (MA) of 8.22, below the 50-day MA of 8.77, and below the 200-day MA of 8.63, indicating a bearish trend. The MACD of -0.21 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 47.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.
JHS Svendgaard Laboratories Limited Peers Comparison
Overall Rating
IN:EMAMILTD74Outperform
IN:COLPAL72Outperform
IN:GODREJCP69Neutral
IN:DABUR67Neutral
IN:HONASA57Neutral
IN:JHS57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | INR 186.65B | 24.93 | ― | 2.58% | 13.15% | -1.27% | |
| 72Outperform | INR 482.77B | 35.48 | ― | 2.70% | 8.72% | 2.71% | |
| 69Neutral | INR 949.77B | 48.09 | ― | 2.15% | 12.02% | 8.49% | |
| 67Neutral | INR 693.62B | 34.21 | ― | 2.30% | 8.94% | 11.89% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 57Neutral | INR 172.72B | 61.02 | ― | 0.57% | 25.70% | 114.58% | |
| 57Neutral | INR 707.99M | -56.30 | ― | ― | 15.61% | 85.89% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:JHS | JHS Svendgaard Laboratories Limited | 8.10 | -2.66 | -24.72% | |
| IN:COLPAL | Colgate-Palmolive (India) Limited | 1775.00 | -347.76 | -16.38% | |
| IN:DABUR | Dabur India Limited | 391.00 | -112.97 | -22.42% | |
| IN:EMAMILTD | Emami Limited | 425.10 | -75.83 | -15.14% | |
| IN:GODREJCP | Godrej Consumer Products Limited | 928.00 | -173.84 | -15.78% | |
| IN:HONASA | Honasa Consumer Limited | 529.35 | 244.33 | 85.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026
